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Abstract
Background: Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes.
It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down
regulated by immunotherapy.
Objective: to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional
(6 weeks), rush (3 days) or ultra rush (1 day).
Methods: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase.
CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT
maintenance.
Results: Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-
rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction,
irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10
significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the
baseline values.
Conclusions: Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes
persist after one year of maintenance treatment.
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Introduction
Allergy is the clinical manifestation of the ‘‘atopic status’’ that
is characterized by an abnormal IgE response to ubiquitous
substances, including pollens, foods, drugs and venoms of
stinging insects. When the contact with the offending allergen
is occasional and isolated (e.g. hymenoptera venom allergy,
HVA, or food allergy) a ‘‘pure’’ IgE-mediated reaction takes
place. This is essentially characterized by the sudden release of
mast cell derived mediators (mainly histamine), triggered by IgE.
The pure IgE-mediated diseases represent a very ‘‘clean’’ model
to study the allergic reaction and its modulation by specific
immunotherapy (SIT). T lymphocytes are responsible for the
‘‘deviation’’ towards the atopic status, and this deviation seems
to be driven by T regulatory (Treg) cells [1,2], so that
impairment in the function of Treg cells may lead to either
autoimmunity or allergy.
Many different signalling molecules intervene in the immune
response, and an increasing interest is currently devoted to the
activationpathwaysofTlymphocytes.AneffectiveT-cellactivation
requiresaprimarysignaldeliveredbytheantigenicpeptidepresented
by major histocompatibility complex molecules and a non-specific
signal(co-stimulation) mediated bythe interactionofCD28withB7
familymembers(CD80,CD86)expressedonantigen-presentingcells
[3]. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a
member of the Ig superfamily, is able to bind B7 antigens, as its
homologue CD28 [3]. There is evidence that CTLA-4, as distinct
from CD28, is a negative regulator of T-cell activation [4]. A native
soluble form of CTLA-4 (sCTLA-4), which may have immunoreg-
ulatory functions [5,6] has also been described. High serum
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various disorders, including autoimmune thyroid diseases, celiac
disease and allergic asthma [6–8]. In addition, we have recently
shownthatsCTLA-4iselevatedintheserumofhymenopteraallergic
patients,anddecreasesaftervenomimmunotherapy(VIT)[9].Inthis
sense,sCTLA-4canberegardedasahallmarkoftheimmunological
effect ofVIT.
VIT can be given according to different regimens, which
essentially differ in the duration of the induction phase. In the
classical protocols (often defined conventional or modified rush),
the build-up lasts 6 weeks or more, whereas in rush regimens the
maintenance dose is achieved in 3 days or less. All those protocols
are similarly effective, but there is no evidence on the timing of the
immunological changes according to the induction. Based on this
background, we assessed and compared the changes in sCTLA-4
induced by different regimens of VIT. Serum IL-10 was also
studied in parallel.
Methods
Patients diagnosed as having HVA, and undergoing different
VIT protocols, were studied. Blood samples were collected as
per routine procedures, and sCTLA-4 and IL-10 were measured
at baseline and immediately after the termination of the
induction phase of VIT. In a subgroup of patients, the assays
were repeated after 12 months of VIT maintenance. The study
is observational, and all the procedures are part of the standard
clinical practice in HVA. Therefore the study was simply
notified to the Ethical Committees of the participating centres,
each using its approved induction protocol, according to the
Italian law. The Ethical Committee approved the study. All
patients (and parents in the case of minors) signed a written
informed consent for the treatment of their personal data, for
the diagnostic procedure and for the vaccination, according to
our routine practice.
Table 1. Characteristics of patients.
Conventional Rush Ultra-rush
N5 0 2 0 2 4
Male/Female 38/12 11/9 20/4
Mean age (range) 48 (16–74) 45,5 (16–69) 35 (9–66)
Grade of reaction
I3 0 2
II 2 5 4
III 26 13 6
IV 19 2 12
VIT Apis mellifera 69 8
VIT Polistes spp 92 4
VIT Vespula spp 34 8 15
VIT Vespa Crabro 11 1
doi:10.1371/journal.pone.0037980.t001
Figure 1. Serum CTLA4 (left) and IL-10 (right) at baseline and at the end of VIT induction phase in the whole population. Values are
expressed as mean and SD. Kruskal-Wallis comparisons are also shown.
doi:10.1371/journal.pone.0037980.g001
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Ninety-four patients with HVA were included in this study. The
diagnosis of HVA was made according to current guidelines [10],
and all centres used the same diagnostic procedures. Prick tests
were performed at increasing concentrations from 0.01 to 100 mg/
mL, and intradermal tests involved the injection of 0.02 mL
extract at 0.001 to 1 mg/mL concentrations. The tests were carried
out with Apis mellifera, Vespula species (Stallerge `nes, Milan, Italy),
Polistes dominulus and Vespa crabro (Anallergo, Florence, Italy). The
Cap-RAST assay was performed with the same venoms.
VIT Protocols
The patients were prescribed with VIT for the responsible
venom, but with different induction protocols as follows: a)
conventional, b) rush, c) ultra-rush. The conventional induction
lasted 6 weeks. On Day 1, increasing doses of 0.01, 0.1, 1 and 3 mg
were administered. The subsequent doses of 10, 20, 40, 75 and
100 mg were given weekly subdivided in two injections. In the rush
protocol the doses were given as follows: 0.01, 0.1, 1 and 3 mgo n
day 1, 5, 10 and 20 mg on day 2, 30, 35, 35 mg on day 3. Injections
were given at 30-minute intervals. The ultra-rush induction lasted
210 minutes. A cumulative dose of 111.1 mg was divided into 6
injections, with an initial dose of 0.1 mg followed by 1, 10 and
20 mg at 30-minute intervals. Then 30 and 40 mg injections were
given every 60 minutes. For all protocols the maintenance dose
was 100 mg, given at 4–6 week intervals, and the planned duration
was 3–5 years as per guidelines.
sCTLA-4 and IL10 Assay
A blood sample was collected at the time of diagnosis (baseline),
and immediately after completing the induction phase of
immunotherapy. In a subset of patients, blood samples were
obtained also after 12 months of maintenance VIT, and in 4
patients receiving the conventional VIT induction, sCTLA4 was
measured every week from baseline to week 6. sCTLA-4 was
measured by an ELISA kit (Bender Med System, Milano, Italy),
according to the manufacturer’s instructions. Each sample was
diluted 1:10 and tested in triplicate. Deviation within triplicates
was ,10% for any reported value. The sensitivity threshold was
0.1 ng/mL. The analytical response was linear approximately
between 0.162 and 1.200 of absorbance values, corresponding to
0.1–50 ng/mL (data not shown). Serum IL-10 was measured by
an ELISA method (Diaclone Research, Besanc ¸on, France). The
lower sensitivity threshold of the method was 5 pg/mL. Specific
IgG4 were assayed by ImmunoCAP Phadia.
Statistical Analysis
The Kruskall-Wallis nonparametric test was used to compare
the paired samples, since a normal distribution could not be
assumed. A p value ,0.05 was considered significant. Nonpara-
Figure 2. Serum CTLA4 at baseline and at the end of the induction. Three different protocols: rush (Panel A), ultra-rush (panel B) and
conventional (panel C).
doi:10.1371/journal.pone.0037980.g002
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doi:10.1371/journal.pone.0037980.g003
Figure 4. Serum CTLA4 at baseline, at the end of induction phase and after 1 year of VIT (mean, SD, and Kruskal-Wallis
comparisons).
doi:10.1371/journal.pone.0037980.g004
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before versus after induction among groups.
Results
Ninety-four patients (69 male and 25 female, mean age 45, age
range 9–74 years) were studied. None of them had a previous
history of anaphylaxis due to food or drugs. Fifty subjects received
the conventional induction (6 weeks), 20 the rush (3 days), and 24
the ultra-rush (24 hours) regimen. VIT was prescribed for the
following venoms: 15 Polistes,6 1Vespula species, 23 Apis Mellifera,3
Vespa Crabro. The main characteristics of the patients in the three
groups are summarized in table 1. Out of 94 patients, 53 had one
or more field re-sting, none during the induction phase. None of
those 53 subjects had systemic reactions of grade II or higher, 12
had a grade I reaction and the remaining had only local reactions.
The overall results of sCTLA4 assays before and after the
induction phase of VIT are reported in Figure 1. According to
our previous observations, all patients showed detectable levels of
sCTLA4 at baseline, although distributed over a wide range of
values. There was no appreciable correlation between baseline
sCTLA4 and severity of the reaction. At the end of VIT induction
sCTLA4 concentrations sharply decreased, irrespective of the
induction protocol used, that is, independently of the duration of
the induction phase (Figure 2). In fact, sCTLA-4 was significantly
reduced as early as 24 hours also in the ultra-rush induction group
(Kruskal-Wallis p,0.001). The percentage change in sCTLA4 did
not differ among the three groups (one way ANOVA: R square
0.0003, p=0.987). At the end of the induction phase the serum
levels of IL-10 were significantly increased with respect to the
baseline values (mean 10,3962,82 pg/mL VS 57,5866,10 pg/
mL; p,0.0001) (Figure 1). Also in this case, the increase was
apparent at the end of the induction phase whatever the induction
protocol (not shown). The percentage change in IL-10 did not
differ among the three groups (one way ANOVA: R square 0.025,
p=0.3427). In the four patients who had sCTLA4 measured week
by week, a sharp decrease of sCTLA-4 could be observed starting
from the first week (Figure 3).
Both sCTLA-4 and IL-10 were measured after 12 months of
maintenance VIT in 69 patients. The concentration of sCTLA-4
remained lower than at baseline at post-induction, with a further
significant decrease at 12 months of maintenance (Kruskal-Wallis
p=0.015) (Figure 4). On the contrary, the concentration of IL-10
at 12 months returned to baseline levels (mean 10,4661,74 VS
10,3962,82 p=ns) (Figure 5).
Discussion
CTLA-4 is recognized as a negative regulator of T-cell
activation. In fact, the binding of CTLA-4 to the T-cell surface
initiates a cascade of biochemical events that attenuates the
ongoing immune response [6]. The most convincing data
supporting such a role for CTLA-4 come from experiments in
knockout mice where the CTLA-4 gene is inactivated [11]. These
mice display severe polyclonal lymphoproliferative disorders that
infiltrate most organs, and die in a few weeks. CTLA-4 may play a
role also in atopy, where the activation of T cells is crucial for the
regulation of the immune response [12,13]. Since CTLA-4 can be
present as a native soluble form in the serum, and sCTLA-4 is able
to bind its ligands and displays functional activities [5,6], we
previously assessed its behaviour in a pure IgE mediated disease
such as HVA [9]. We showed that sCTLA-4 was increased in all
patients with HVA, but not in respiratory allergy or in healthy
subjects. Of note, the role of sCTLA-4 is not well ascertained in
respiratory allergy, as demonstrated by controversial results [14–
16]. On the other hand, CTLA-4 appears to be consistently
elevated in HVA and sharply decreased after the induction phase
of VIT. This reduction parallels the increase in IL-10 [9]. As such,
Figure 5. Serum IL-10 at baseline, at the end of induction phase and after 1 year of VIT (mean, SD, Kruskal-Wallis comparison).
doi:10.1371/journal.pone.0037980.g005
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respect to healthy subjects and patients with allergic respiratory
diseases. In the present study we aimed at assessing if the duration
of the VIT induction phase influences the behavior of circulating
sCTLA-4, and if there are modifications on the long-term. We
observed that the decrease in CTLA-4 is a very early phenomenon
that occurs immediately after induction whatever the induction
protocol: the faster was the induction, the earlier sCTLA4
decrease. The magnitude of decrease seems to be merely related
to the amount of allergen administered, without any relationship
with induction timing. Long-term follow-up demonstrated that
sCTLA4 concentrations remained low as long as 12 months after
starting VIT. Of note, the changes in IL-10 are very early, within
24 hours. On the other hand IL-10 returned to baseline level after
one year, thus suggesting that this cytokine intervenes only in the
early phases of specific immunotherapy [17], whereas sCTLA4
testifies for the persistence of the immunologic effects of
vaccination.
Thus, although the two phenomena (sCTLA4 decrease and
IL10 rise) occur abruptly and nearly simultaneously, they are not
strictly dependent between each other, in other words, sustained
IL10 secretion is not required to maintain low sCTLA4 levels in
serum. This is perhaps not surprising, since it is well conceivable
that other cytokines/regulatory signals play some role. It is worth
noting, in addition, that IL10 secretion following VIT is likely due
to different cell types (T-cells and monocytes) with different timing
and kinetics [18,19]. In any case, we hypothesize that sCTLA4
reduction may reflect subsiding of sustained T-cell activation in
patients under VIT maintenance. It is conceivable that production
of sCTLA4 primarily depends upon T- cell activation (irrespective
to their specificity or cytokine secretion capability), and that
sCTLA4, which proved to be a functional molecule, plays a role in
perpetuating the activation state of T-cells by interfering with
negative signalling through membrane CTLA4 [6]. Thus, VIT,
that is expected to redirect the immune response to the allergen(s),
results in stable reduction of sustained activation state of T-cells.
Of note, it is possible that sCTLA4 also derives from cell types
other than T-lymphocytes; in addition and more importantly, as
previously discussed [6] the interaction of sCTLA4 with resting T-
cells may act in an inhibitory way, by interfering with stimulatory
signalling through membrane CD28 expressed by resting T-cells.
In conclusion, serum sCTLA4 reduction following VIT
induction, whatever the protocol used, is a very early marker of
VIT effectiveness, and it is possible to envisage that the persistence
of low sCTLA4 levels indicates sustained protection against
clinical reactions to field-resting.
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